Get the Stockscreener App
27.88
2.04%
-0.58
Pre-market:
28.92
1.04
+3.73%
Evommune Inc stock is traded at $27.88, with a volume of 552.81K.
It is down -2.04% in the last 24 hours and up +31.88% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$28.46
Open:
$27.7
24h Volume:
552.81K
Relative Volume:
1.14
Market Cap:
$878.89M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+67.35%
1M Performance:
+31.88%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$26.42
$30.68
1-Week Range:
$15.97
$33.20
52-Week Range:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
27.88 | 897.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune to Raise $125 Million Via Private Placement - marketscreener.com
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com India
Evommune raises $125M privately - MSN
Evommune's stock surges on strong results for new eczema drug - MSN
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com Nigeria
Evommune Announces $125 Million Private Placement - Business Wire
Evommune Enters Private Placement Agreement for $125 Million - Intellectia AI
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Bitget
Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis - simplywall.st
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge (NYSE:EVMN) - Seeking Alpha
Evommune’s stock rallies 70% on Phase IIa eczema data - Yahoo Finance
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Magazine
Evommune stock price slips premarket after 71% jump on eczema drug data - Bez Kabli
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial By Investing.com - Investing.com South Africa
Evommune soars on mid-stage atopic dermatitis data - FirstWord Pharma
Evommune, Nektar assets join list of recent successes in atopic derm - biocentury.com
H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026 - Meyka
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Health Care Stocks Split As Evommune Pops On Eczema Data - Finimize
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis - MedCity News
EVMN Stock Rating: Analyst Mitchell S. Kapoor Raises Price Targe - GuruFocus
Evommune stock price target raised to $55 by Evercore ISI on positive trial data By Investing.com - Investing.com India
Evommune stock price target raised to $55 by Evercore ISI on positive trial data - Investing.com
Evommune (NYSE:EVMN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Evommune (NYSE:EVMN) Sets New 1-Year HighHere's What Happened - MarketBeat
Why Is Evommune Stock Soaring Today?Evommune (NYSE:EVMN) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune Stock Soars 51% Over Positive Top-Line Data From Atopic Dermatitis Study - Nasdaq
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate - PharmiWeb.com
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial - BioSpace
Evommune Says Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial; Shares Rise - marketscreener.com
Evommune wins in mid-stage trial for eczema drug (EVMN:NYSE) - Seeking Alpha
Evommune reports positive mid-stage data for eczema drug - statnews.com
EVMN: EVO301 achieved significant efficacy and safety in Phase 2a atopic dermatitis trial - TradingView
Evommune's Dupixent-like eczema data drive 75% stock rally - Fierce Biotech
Evommune Advances EVO301 After Positive Phase 2a Results - TipRanks
Evommune, Inc. Announces Positive Phase 2a Trial Results for EVO301 in Atopic Dermatitis - TradingView
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com UK
Evommune reports EVO301 trial met primary endpoint - TipRanks
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Yahoo Finance Singapore
Evommune Secures $125 Million in Private Placement - Intellectia AI
Evommune (NYSE:EVMN) Stock Price Down 5.3%Time to Sell? - MarketBeat
Evommune (NYSE:EVMN) Trading 10% HigherWhat's Next? - MarketBeat
Evommune (NYSE:EVMN) Shares Down 6.9%Here's Why - MarketBeat
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of Evommune (EVMN) with Outperform Recommendation - Nasdaq
Evommune (NYSE:EVMN) Now Covered by Oppenheimer - MarketBeat
Evommune Inc Stock (EVMN) Financials Data
There is no financial data for Evommune Inc (EVMN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):